Michelle K Yong1,2, Paul U Cameron1,2, Monica Slavin2,3,4, C Orla Morrissey1,5, Krystal Bergin5, Andrew Spencer5, David Ritchie6,7, Allen C Cheng1, Assia Samri8,9, Guislaine Carcelain8,9, Brigitte Autran8,9, Sharon R Lewin1,2. 1. Department of Infectious Diseases, Monash University and Alfred Hospital. 2. Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital. 3. Victorian Infectious Diseases Service, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity. 4. Peter MacCallum Cancer Centre. 5. Department of Haematology, Monash University and Alfred Hospital. 6. Department of Clinical Haematology and Bone Marrow Transplant Service, Royal Melbourne Hospital. 7. Department of Medicine, University of Melbourne, Melbourne, Australia. 8. Institut National de la Sante et de la Recherche Medicale, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Universités, University Pierre et Marie Curie. 9. Assistance Publique-Hopitaux de Paris, Hôpital Pitié-Salpêtrière, Département d'Immunologie, France.
Abstract
Background: A simple test to identify recovery of CMV-specific T-cell immunity following hematopoietic stem cell transplantation (HSCT) could assist clinicians in managing CMV-related complications. Methods: In an observational, multicenter, prospective study of 94 HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9, and 12 months after transplant using the Quantiferon-CMV, an enzyme-linked immunosorbent spot assay (ELISpot), and intracellular cytokine staining. Results: At 3 months after HSCT, participants who developed CMV disease (n = 8) compared with CMV reactivation (n = 26) or spontaneous viral control (n = 25) had significantly lower CD8+ T-cell production of interferon-γ (IFN-γ) in response to CMV antigens measured by Quantiferon-CMV (P = .0008). An indeterminate Quantiferon-CMV result had a positive predictive value of 83% and a negative predictive value of 98% for identifying participants at risk of further CMV reactivation. Participants experiencing CMV reactivation compared with patients without CMV reactivation had a reduced proportion of polyfunctional (IFN-γ+/tumor necrosis factor α-positive) CD4+ and CD8+ T cells and a higher proportion of interleukin 2-secreting cells (P = .01 and P = .002, respectively). Conclusions: Quantifying CMV-specific T-cell immunity after HSCT can identify participants at increased risk of clinically relevant CMV-related outcomes.
Background: A simple test to identify recovery of CMV-specific T-cell immunity following hematopoietic stem cell transplantation (HSCT) could assist clinicians in managing CMV-related complications. Methods: In an observational, multicenter, prospective study of 94 HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9, and 12 months after transplant using the Quantiferon-CMV, an enzyme-linked immunosorbent spot assay (ELISpot), and intracellular cytokine staining. Results: At 3 months after HSCT, participants who developed CMV disease (n = 8) compared with CMV reactivation (n = 26) or spontaneous viral control (n = 25) had significantly lower CD8+ T-cell production of interferon-γ (IFN-γ) in response to CMV antigens measured by Quantiferon-CMV (P = .0008). An indeterminate Quantiferon-CMV result had a positive predictive value of 83% and a negative predictive value of 98% for identifying participants at risk of further CMV reactivation. Participants experiencing CMV reactivation compared with patients without CMV reactivation had a reduced proportion of polyfunctional (IFN-γ+/tumor necrosis factor α-positive) CD4+ and CD8+ T cells and a higher proportion of interleukin 2-secreting cells (P = .01 and P = .002, respectively). Conclusions: Quantifying CMV-specific T-cell immunity after HSCT can identify participants at increased risk of clinically relevant CMV-related outcomes.
Authors: Michelle K Yong; Paul U Cameron; Monica A Slavin; Allen C Cheng; C Orla Morrissey; Krystal Bergin; Andrew Spencer; David Ritchie; Sharon R Lewin Journal: Front Immunol Date: 2017-11-09 Impact factor: 7.561
Authors: Harini D de Silva; Rosemary A Ffrench; Maya Korem; Eva Orlowski; David J Curtis; Andrew Spencer; Sharon Avery; Sushrut Patil; Catherine Orla Morrissey Journal: Clin Transl Immunology Date: 2018-10-05
Authors: María Iglesias-Escudero; Marco Antonio Moro-García; Raquel Marcos-Fernández; Alejandra García-Torre; Marta Elena Álvarez-Argüelles; María Luisa Suárez-Fernández; Pablo Martínez-Camblor; Minerva Rodríguez; Rebeca Alonso-Arias Journal: PLoS One Date: 2018-04-11 Impact factor: 3.240